Download PDF
CC BY-NC-ND 4.0 · Indian J Radiol Imaging 2017; 27(02): 200-206
DOI: 10.4103/ijri.IJRI_24_17
Intervention Radiology & Vascular

Early outcomes of radiofrequency ablation in unresectable metastatic colorectal cancer from a tertiary cancer hospital in India

Suyash Kulkarni
Department of Radio-diagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Nitin S Shetty
Department of Radio-diagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Ashwin M Polnaya
Department of Radio-diagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Sushil Patil
Department of Radio-diagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Kunal Gala
Department of Radio-diagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Rahul Chivate
Department of Radio-diagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Vikas Ostwal
Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Anant Ramaswamy
Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Shailesh V Shrikhande
Department of Surgical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Mahesh Goel
Department of Surgical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Shraddha Patkar
Department of Surgical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Manish Bhandare
Department of Surgical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Venkatesh Rangarajan
Department of Nuclear Medicine, Tata Memorial Centre, Mumbai, Maharashtra, India
,
Purandare Nilendu
Department of Nuclear Medicine, Tata Memorial Centre, Mumbai, Maharashtra, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Aims: The study was carried out to evaluate the early outcomes using Radiofrequency Ablation (RFA) for unresectable liver metastases in the management of metastatic colorectal cancer (mCRC) from an area of low endemicity. Material and Methods: 60 Patients with unresectable colorectal liver metastases had undergone 88 sessions of RFA from January 2007 till December 2013. The results were retrospectively analysed to evaluate the outcomes in terms of efficacy and survival rates. Results: The median follow up of patients in our series was 24.8months. 35/52 (67.3%) patients had complete response at 3 months while 8 patients were lost to follow up. Of the 17 patients who had recurrence, 4 (23.5%) were at the ablated site while 13 patients (76.4%) progressed elsewhere. Abdominal pain was commonest post procedural symptom (20%). There was no procedure related mortality or any major complications. Mean disease free interval and Progression free survival was 6.7 and 13.1 months. Estimated median survival in patients with liver limited disease and those with small lesion (<3cm) was 3.79 years and 3.45 years respectively. Median survival in patients with lesion size 3–5 cms was 1.5 years. Annual survival rates would be 94.5%, 55.2% and 26.2% for 1, 3 and 5 years. Conclusion: Radiofrequency ablation of unresectable liver metastases is effective in treatment of mCRC. Estimated survival rates and Annual survival rates at our institute from the low endemic region also follow the global trend. Size of the lesion was an important predictor of efficacy of RFA. Presence of extrahepatic disease and lesion size >3 cm was associated with decreased survival.

Keywords

Radiofrequency ablation - unresectable colorectal liver metastases - metastatic colorectal cancer - Liver radiofrequency ablation


Publication History

Article published online:
27 July 2021

© 2017. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 House MG, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: Trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 2010; 210(5):744–5.
  • 2 de Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreux M, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol 2000;175:1619-25.
  • 3 Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-27.
  • 4 Hughes KS, Rosenstein RB, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, et al. Resection of the liver for colorectal carcinoma metastases: A multi-institutional study of long-term survivors. Dis Colon Rectum 1988;31:1-4.
  • 5 Scheele J, Rudroff C, Altendorf-Hofman A. Resection of colorectal liver metastases revisited. J Gastrointestinal Surg 1997;1:408-22.
  • 6 Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999;230:309–18.
  • 7 Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer. Ann Surg 1984;199:502–7.
  • 8 Federica Zoratto, Luigi Rossi, Angelo Zullo, Anselmo Papa Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther. 2012;5:199-211.
  • 9 Gillams AR, Lees WR. Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases. J Vasc Interv Radiology. 2008 May; 19(5):712-7.
  • 10 Sergio S, Paola T, Francesca M, Ingrid N, Davide T, Mirella C, et al. Subcapsular Liver Tumors Treated with Percutaneous Radiofrequency Ablation: A Prospective Comparison with Nonsubcapsular Liver Tumors for Safety and Effectiveness. Radiology 2008; 248:670-9.
  • 11 Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, et al. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: Evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 2006;12:318-26.
  • 12 Langenhoff BS, Oyen WJ, Jager GJ, Strijk SP, Wobbes T, Corstens FH, et al. Efficacy of fluorine-18-deoxyglucosepositron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: A prospective study. J Clin Oncol 2002;20:4453-8.
  • 13 Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis- meta-analysis. Radiology 2005; 237:123-31.
  • 14 Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003;28:192-7.
  • 15 Donckier V, Van Laethem JL, Goldman S, Van Gansbeke D, Feron P, Ickx B, et al. [F-18] fluoro deoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 2003; 84:215-23.
  • 16 Chen W, Zhuang H, Cheng G, Torigian DA, Alavi A. Comparison of FDG-PET, MRI and CT for post radiofrequency ablation evaluation of hepatic tumors. Ann Nucl Med 2013;27:58-65.
  • 17 Kuehl H, Antoch G, Stergar H, Veit-Haibach P, Rosenbaum-Krumme S, Vogt F, Frilling A, Barkhausen J, Bockisch A. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: Initial results. European Journal of Radiology. 2008 Aug; 67(2):362-71.
  • 18 Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: A randomized EORTC intergroup phase II study (EORTC 40004). Ann oncol 2012; 23:2619-26.
  • 19 Babawale SN, Jensen TM, Frokjaer JB. Long-term survival following radiofrequency ablation of colorectal liver metastases: A retrospective study. World J Gastrointest Surg. 2015 Mar 27; 7(3):33-8.
  • 20 Solbiati L, Ahmed M, Cova L, Ierace T, Brioschi M, Goldberg SN, et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: Local response rate and long-term survival with up to 10-year follow-up. Radiology. 2012 Dec; 265(3):958-68.
  • 21 Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Annals of Surgery 2007;246:559-65.